Literature DB >> 15914128

Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.

Christine Klipping1, Joachim Marr.   

Abstract

OBJECTIVE: To compare the effect of ethinyl estradiol 20 microg/drospirenone 3 mg (EE 20 microg/DRSP 3 mg) administered according to a 24/4 regimen with ethinyl estradiol 20 microg/desogestrel 150 microg (EE 20 microg/DSG 150 microg) administered according to the conventional 21/7 regimen on lipid, carbohydrate and hemostatic parameters. STUDY
DESIGN: In this open-label study, healthy women were randomized to EE 20 microg/DRSP 3 mg or EE 20 microg/DSG 150 microg for seven cycles. Mean differences in high-density lipoprotein (HDL)- and low-density lipoprotein (LDL)-cholesterol levels at cycle 7 compared to baseline were assessed. Secondary variables included changes in other lipid, hemostatic and carbohydrate parameters.
RESULTS: Both treatments increased HDL-cholesterol, but decreased LDL-cholesterol by a comparable extent. Although slightly elevated in both groups, blood glucose and C-peptide levels measured during oral glucose tolerance tests were within normal reference ranges at cycle 7. Overall, the differences in lipid, hemostatic or carbohydrate parameters were not significant between the two treatments.
CONCLUSION: EE 20 microg/DRSP 3 mg has a good safety profile comparable with EE 20 microg/DSG 150 microg.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914128     DOI: 10.1016/j.contraception.2004.12.005

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  19 in total

1.  Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.

Authors:  Wolfgang Junge; Uwe Mellinger; Susanne Parke; Marco Serrani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.

Authors:  Leena Anttila; Walter Neunteufel; Felice Petraglia; Joachim Marr; Michael Kunz
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Influence of oral contraceptives on lipid profile and paraoxonase and commonly hepatic enzymes activities.

Authors:  Katarzyna Kowalska; Milena Ściskalska; Anna Bizoń; Mariola Śliwińska-Mossoń; Halina Milnerowicz
Journal:  J Clin Lab Anal       Date:  2017-03-09       Impact factor: 2.352

4.  Effect of injectable and oral contraceptives on glucose and insulin levels.

Authors:  Abbey B Berenson; Patricia van den Berg; Karen J Williams; Mahbubur Rahman
Journal:  Obstet Gynecol       Date:  2011-01       Impact factor: 7.661

Review 5.  Metabolic effects of contraceptive steroids.

Authors:  Regine Sitruk-Ware; Anita Nath
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

6.  A combined oral contraceptive containing 30 mcg ethinyl estradiol and 3.0 mg drospirenone does not impair endothelium-dependent vasodilation.

Authors:  Jessica R Meendering; Britta N Torgrimson; Nicole P Miller; Paul F Kaplan; Christopher T Minson
Journal:  Contraception       Date:  2010-04-27       Impact factor: 3.375

7.  Effect of injectable and oral contraceptives on serum lipids.

Authors:  Abbey B Berenson; Mahbubur Rahman; Gregg Wilkinson
Journal:  Obstet Gynecol       Date:  2009-10       Impact factor: 7.661

Review 8.  Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome.

Authors:  E Carmina
Journal:  J Endocrinol Invest       Date:  2013-02-27       Impact factor: 4.256

Review 9.  Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Authors:  Caroline Fenton; Keri Wellington; Marit D Moen; Dean M Robinson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin.

Authors:  Gloria Bachmann; Sharon Kopacz
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.